Should rasagiline be discontinued when a patient with Parkinson's disease develops a fever?

Rasagiline Should NOT Be Routinely Stopped During Fever in Parkinson's Disease

Rasagiline does not need to be discontinued when a Parkinson's disease patient develops a fever, unless there are specific concerning features suggesting serotonin syndrome or neuroleptic malignant syndrome-like presentation. The FDA label for rasagiline does not list fever as a contraindication or reason for discontinuation 1.

Key Clinical Considerations

When to Continue Rasagiline

• Simple fever alone (from infection, inflammation, or other common causes) is not an indication to stop rasagiline
• The drug can be safely continued during routine febrile illnesses
• No specific drug-fever interaction is documented in the FDA labeling 1

When to Consider Stopping Rasagiline

Immediately discontinue if the patient develops withdrawal-emergent hyperpyrexia and confusion, which is a rare but serious syndrome resembling neuroleptic malignant syndrome characterized by 1:

• Elevated temperature with muscular rigidity
• Altered consciousness
• Autonomic instability
• This typically occurs with rapid dose reduction or withdrawal of rasagiline, not during continued use

Exercise extreme caution if fever occurs with:

• Mental status changes (confusion, agitation, delirium)
• Neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity)
• Autonomic hyperactivity (hypertension, tachycardia, diaphoresis)
• These features suggest serotonin syndrome, especially if the patient is on concomitant serotonergic medications 2, 3

Critical Drug Interactions During Fever

If the febrile patient requires antibiotics, avoid or use extreme caution with:

• Linezolid - can exacerbate serotonin syndrome 4
• Ciprofloxacin - increases rasagiline levels up to 2-fold; if unavoidable, reduce rasagiline to 0.5 mg daily 1

Practical Management Algorithm

1. Assess the fever etiology: Determine if infectious, inflammatory, or drug-related 4

2. Evaluate for warning signs:

   • Check for serotonin syndrome features (myoclonus, clonus, hyperreflexia, diaphoresis, confusion)
   • Assess for NMS-like features (severe rigidity, altered consciousness, autonomic instability)
   • Review all concurrent medications, especially antidepressants, opioids, or other serotonergic agents

3. Continue rasagiline if:

   • Fever is from a clear infectious or inflammatory source
   • No concerning neuropsychiatric or autonomic features present
   • Patient is clinically stable

4. Stop rasagiline immediately if:

   • Signs of serotonin syndrome develop
   • Withdrawal-emergent hyperpyrexia syndrome suspected
   • Severe unexplained fever with rigidity and altered consciousness

Common Pitfalls to Avoid

• Do not reflexively stop rasagiline for every fever - this may precipitate withdrawal syndrome, which itself can cause severe psychiatric symptoms (depression, anxiety, panic attacks, dysphoria, agitation) and autonomic manifestations 5
• Abrupt discontinuation carries risks - withdrawal syndrome has been documented with rasagiline cessation 5
• Monitor closely if stopping - if discontinuation is necessary, watch for withdrawal symptoms including severe mood disturbances, anxiety, generalized pain, and autonomic dysfunction 5

The evidence does not support routine discontinuation of rasagiline during fever in Parkinson's disease patients. Continue the medication unless specific contraindications or concerning syndromic features develop.